Meuth Sven G, Vila Carlos, Dechant Kerry L
Department of Neurology, University of Münster, Albert-Schweitzer Campus 1, 48149 Münster, Germany.
Expert Rev Neurother. 2015;15(8):909-18. doi: 10.1586/14737175.2015.1067607. Epub 2015 Jul 11.
Individuals with multiple sclerosis (MS) spasticity may experience a range of symptoms, such as bladder dysfunction, pain, impaired sleep quality and mobility restrictions that worsen as spasticity severity increases. In this review, the effects of Sativex(®) oromucosal spray on symptoms and functional impairment associated with MS-related spasticity were examined. Across Sativex studies, there was a clear trend for improvement in spasticity-associated symptoms that was more pronounced and sustained over time in Sativex responders. Meaningful symptomatic improvement was achieved within the recommended dosage limit of ≤12 sprays per day. In appropriate patients, Sativex has the potential to minimize the consequences of spasticity-related symptoms on quality of life and reduce the economic burden on healthcare systems.
患有多发性硬化症（MS）痉挛的个体可能会出现一系列症状，如膀胱功能障碍、疼痛、睡眠质量受损和行动受限，且随着痉挛严重程度的增加而恶化。在本综述中，研究了Sativex®口腔黏膜喷雾剂对与MS相关痉挛相关的症状和功能损害的影响。在各项Sativex研究中，与痉挛相关症状改善的明显趋势在Sativex反应者中随着时间的推移更为显著且持续。在每天≤12喷的推荐剂量限制内实现了有意义的症状改善。在合适的患者中，Sativex有潜力将与痉挛相关症状对生活质量的影响降至最低，并减轻医疗保健系统的经济负担。
